UPDATE: Morgan Stanley Reiterates On Cardinal Health On Dublin Day Takeaways

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Cardinal Health CAH, but removed the $76.00 price target. In the report, Morgan Stanley noted, “Contribution from CVS JV should ramp through FY15 with benefit weighted towards 2H, reaching full run-rate in FY16. Lines between channels of trade will likely continue to blur as scale becomes most critical. Importantly the CVS JV provides manufacturers with access to 3 channels (retail, distributor, and mail). JV structure has been well received by existing customers. Longer term, as the gap between top 3-4 buyers and the rest widens, larger pharmacies likely to rethink existing self-warehousing generic strategy.” Cardinal Health closed on Tuesday at $66.20.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsMorgan StanleyRicky R. Goldwasser
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!